Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 6/20 | 0.95 |
| ▸ | CD44 | P16070 | 2/20 | 0.95 |
| ▸ | MAOB | P27338 | 1/20 | 0.95 |
| ▸ | HTR2C | P28335 | 1/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.52 |
| ▸ | PRCP | P42785 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL28236302 | 0.97 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL19085 | 0.97 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL29360217 | 0.97 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL4243903 | 0.95 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL11457582 | 0.95 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL5411332 | 0.95 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL987515 | 0.95 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL11213530 | 0.95 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL6635293 | 0.95 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| SCHEMBL11838922 | 0.95 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230107256-A1 | QUINOLINE DERIVED SMALL MOLECULE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-06 | — | — | US | disclosed |
| US-20200102274-A1 | QUINOLINE DERIVED SMALL MOLECULE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2020-04-02 | — | — | US | disclosed |
| EP-3600317-A1 | QUINOLINE DERIVED SMALL MOLECULE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF | The Board of Regents of The University of Texas System (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018183668-A1 | QUINOLINE DERIVED SMALL MOLECULE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-10-04 | — | — | WO | disclosed |
| CN-101675051-A | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors | WYETH CORP | 2010-03-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102274-A1 | QUINOLINE DERIVED SMALL MOLECULE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF | NNMT, NAMPT, NNT | PNMT 17/4885CD44 4815/4885MAOB 271/4885 |
| US-20230107256-A1 | QUINOLINE DERIVED SMALL MOLECULE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF | NNMT, NAMPT, NNT | PNMT 13/4885CD44 4776/4885MAOB 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.